Structured evidence table for Palmitoylethanolamide Joint Discomfort Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Palmitoylethanolamide Joint Discomfort Randomized Trial | However, several issues are implicated in the feasibility of these methods, for instance, inhibiting the hydrolases may result in a restriction of recycling back of the precursor molecules back to the membrane (). | 3 | Zia Bushra (2026) | Therapeutic potential, pharmacological role and molecular mechanisms of adelmidrol, an analogue of palmitoylethanolamide |
| Palmitoylethanolamide Joint Discomfort Randomized Trial | Experimental evidence from a mouse model indicates that adelmidrol effectively raises the concentration of N-acylethanolamides in tissue subsequently leading to an enhancement in the endogenous PEA levels in the duodenum and colon in a time and dose dependent manner (). | 3 | Zia Bushra (2026) | Therapeutic potential, pharmacological role and molecular mechanisms of adelmidrol, an analogue of palmitoylethanolamide |
| Palmitoylethanolamide Joint Discomfort Randomized Trial | demonstrated that adelmidrol improves lung function by downregulating specific markers associated with the activation of mast cells (chymase, tryptase) and upregulating antioxidant enzymes through NF-κB pathway modulation (). | 3 | Zia Bushra (2026) | Therapeutic potential, pharmacological role and molecular mechanisms of adelmidrol, an analogue of palmitoylethanolamide |
| Palmitoylethanolamide Joint Discomfort Randomized Trial | Cerrato et al., 2012 Petrosino and Di Marzo, 2017 Piomelli et al., 2006 Ahn et al., 2009 Del Re et al., 2022 Cordaro et al., 2016a De Filippis et al., 2009 Della Rocca and Re, 2022 della Rocca and Re, 2022 Pulvirenti et al., 2007 Fig. | 3 | Zia Bushra (2026) | Therapeutic potential, pharmacological role and molecular mechanisms of adelmidrol, an analogue of palmitoylethanolamide |
| Palmitoylethanolamide Joint Discomfort Randomized Trial | Recent evidence highlights the contribution of angiogenesis and lymph-angiogenesis to Nickel-induced allergic contact dermatitis, through crosstalk among keratinocytes, mast cells, endothelial cells, and pro-angiogenic mediators such as vascular endothelial growth factor. | 4 | Palenca I (2026) | Palmitoylethanolamide for Nickel Allergy: Plausible, Untested, and Worth Considering. |
| Palmitoylethanolamide Joint Discomfort Randomized Trial | Nickel allergy remains the most prevalent cause of allergic contact dermatitis worldwide, imposing a substantial socio-epidemiological and economic burden. | 4 | Palenca I (2026) | Palmitoylethanolamide for Nickel Allergy: Plausible, Untested, and Worth Considering. |
| Palmitoylethanolamide Joint Discomfort Randomized Trial | Beyond its classical cutaneous presentation, systemic nickel allergy syndrome highlights the systemic dimension of Nickel hypersensitivity, wherein dietary nickel intake may provoke both gastrointestinal and cutaneous symptoms through mechanisms involving gut barrier impairment and mucosal immune priming. | 4 | Palenca I (2026) | Palmitoylethanolamide for Nickel Allergy: Plausible, Untested, and Worth Considering. |
Source documents